Generic Name and Formulations:
Ambenonium chloride 10mg; tabs.
Indications for MYTELASE:
Individualize. Usual range: 5–25mg 3 or 4 times daily. Increase gradually at intervals of 1–2 days. Some patients may require 50–75mg per dose. Increasing dosage above 200mg daily requires supervision by clinician aware of signs and treatment of overdose.
Concomitant atropine, mecamylamine, or any other ganglionic blocking agents.
Monitor closely; narrow margin between first appearance of side effects and serious toxic effects. Asthma. Parkinson's disease. Mechanical intestinal or urinary obstruction. Bradycardia. Cardiac conduction disorders. Elderly. Pregnancy. Nursing mothers: not recommended.
Overdosage (eg, excessive salivation, abdominal cramps, diarrhea, miosis, urinary urgency, sweating, nausea, increase in bronchial and lacrymal secretions, vomiting, muscle cramps, fasciculation of voluntary muscles, generalized malaise, anxiety, vertigo).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Nicotinamide and Cancer
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML